metformin + pioglitazone hydrochloride: clinical use

Prescribing considerations

• Confirm that metformin monotherapy at the maximum tolerated level has not achieved sufficient control and consider titrating the individual components before switching to the fixed combination.
• Assess heart-failure, bladder-cancer and fracture risk, particularly in older adults.
• Review response after initiation and discontinue pioglitazone if benefit is inadequate; confirm continued benefit during routine reviews.
• Temporarily interrupt treatment during significant dehydration and around relevant surgery or intravascular iodinated contrast procedures.
• Pioglitazone may restore ovulation in insulin-resistant patients; discuss pregnancy risk where relevant.

Contraindications and cautions

• Current or previous heart failure
• Current or previous bladder cancer, or unexplained visible haematuria
• Hepatic impairment
• Severe renal impairment
• Acute metabolic acidosis, including diabetic ketoacidosis or lactic acidosis
• Acute conditions that may impair renal function, including dehydration, severe infection or shock
• Diseases causing tissue hypoxia, including cardiac or respiratory failure, recent myocardial infarction or shock
• Acute alcohol intoxication or alcoholism
• Pregnancy and breastfeeding
• Hypersensitivity to an active ingredient or excipient

Monitoring

• Assess HbA1c, weight, liver function, renal function and visible haematuria risk before treatment.
• Monitor renal function regularly and more frequently in older adults or those at risk of deterioration.
• Review HbA1c response after three to six months and periodically reassess whether pioglitazone benefit continues.
• Monitor weight and symptoms of oedema or heart failure.
• Monitor liver enzymes periodically and investigate symptoms of hepatic dysfunction.
• Check vitamin B12 when deficiency is suspected; periodic measurement may be appropriate in people with risk factors.
• Arrange ophthalmic assessment for new or worsening visual acuity disturbance.

Clinical pharmacology

Metformin suppresses hepatic gluconeogenesis, modestly improves peripheral insulin sensitivity and delays intestinal glucose absorption; it is eliminated unchanged by the kidneys. Pioglitazone is a PPAR-gamma agonist that reduces insulin resistance and undergoes extensive hepatic metabolism, mainly through CYP2C8. The fixed product is bioequivalent to the individual components administered separately.

Formulation and product differences

• The selected product is a fixed-ratio, immediate-release, film-coated tablet containing both active ingredients.
• A fixed combination may be unsuitable when renal function or tolerability requires independent adjustment of the two components.
• The tablet is essentially sodium-free and is supplied in aluminium blisters.

Tablet

Route: Oral

Strengths: 15 mg + 850 mg